Richard M. Siegel, M.D., Ph.D.

Senior Investigator

Autoimmunity Branch

NIAMS

Clinical Director

NIAMS

Building 10, Room 13C103A
10 Center Drive
Bethesda, MD 20814

301-496-3761

siegelr@mail.nih.gov

Research Topics

The goal of the Immunoregulation Group is to understand how alterations in regulatory signaling pathways in immune cells lead to abnormal immune responses, chronic inflammation, and autoimmune diseases. The TNF family of cytokines is the main focus of present work, as these cytokines are critical in the pathogenesis and treatment of a number of different autoimmune and inflammatory diseases. We are particularly interested in how membrane-proximal events in receptor signal transduction can be influenced by environmental or other signals to alter cellular responses, since understanding these principles may aid in designing more effective therapeutic strategies to modulate the effects of TNF-receptor family signaling in autoimmune and inflammatory diseases.   The general strategy of the lab is to better understand basic mechanisms of transmembrane signal transduction by selected TNF family receptors using the both cell and molecular biology approaches. We are also interested in studying the role of particular TNF family ligand-receptor systems in immune cells through mouse models.

Biography

Richard Siegel's interest in immunology and apoptosis began in the late 1980's at the University of Pennsylvania School of Medicine where he was an M.D., Ph.D. student. Working with Mark Greene and John Reed, he studied the influence of bcl-2 on T cell apoptosis and repertoire selection. He trained in Internal Medicine and Rheumatology at Hospital of the University of Pennsylvania, and moved to the NIH in 1996 to do postdoctoral training with Michael Lenardo in the Laboratory of Immunology in the National Institute of Allergy and Infectious Disease. There he studied apoptosis signaling and the molecular basis of its impairment in patients with inherited mutations in Fas/CD95 and the Autoimmune Lymphoproliferative Syndrome (ALPS). In 2001, Dr. Siegel moved to NIAMS as a tenure-track investigator. His current research interests include regulation of cellular survival and death in the immune system by TNF receptor and other signaling pathways, and the relevance of these pathways to autoimmune diseases and immune tolerance. He is a member of the American Society of Clinical Investigation and serves on the editorial board of the Journal of Biological Chemistry.

Selected Publications

  1. Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY, Sack MN, Kastner DL, Siegel RM. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med. 2011;208(3):519-33.

  2. Cruz AC, Ramaswamy M, Ouyang C, Klebanoff CA, Sengupta P, Yamamoto TN, Meylan F, Thomas SK, Richoz N, Eil R, Price S, Casellas R, Rao VK, Lippincott-Schwartz J, Restifo NP, Siegel RM. Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction. Nat Commun. 2016;7:13895.

  3. Meylan F, Hawley ET, Barron L, Barlow JL, Penumetcha P, Pelletier M, Sciumè G, Richard AC, Hayes ET, Gomez-Rodriguez J, Chen X, Paul WE, Wynn TA, McKenzie AN, Siegel RM. The TNF-family cytokine TL1A promotes allergic immunopathology through group 2 innate lymphoid cells. Mucosal Immunol. 2014;7(4):958-68.

  4. Simon A, Park H, Maddipati R, Lobito AA, Bulua AC, Jackson AJ, Chae JJ, Ettinger R, de Koning HD, Cruz AC, Kastner DL, Komarow H, Siegel RM. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci U S A. 2010;107(21):9801-6.

  5. Meylan F, Davidson TS, Kahle E, Kinder M, Acharya K, Jankovic D, Bundoc V, Hodges M, Shevach EM, Keane-Myers A, Wang EC, Siegel RM. The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity. 2008;29(1):79-89.


This page was last updated on September 28th, 2017